Study guide
1.3 Neurotransmitters, Neuromodulators, and Psychopharmacology
GRE Subject Test: Psychology Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Neuroanatomy, Neural Transmission, and Neuroscience Methods
1.1 Cellular Neuroscience: Neurons, Action Potentials, and Synaptic Transmission 1.2 Functional Neuroanatomy: Brain Structures, Hemispheric Specialization, and Cortical Lobes 1.3 Neurotransmitters, Neuromodulators, and Psychopharmacology 1.4 The Endocrine System, Autonomic Nervous System, and Behavioral Genetics 1.5 Cognitive Neuroscience Methods, Lateralization Testing, and Neuroplasticity
2 Chapter 2: Sensation and Perception
2.1 Psychophysics, Sensory Thresholds, and Signal Detection Theory 2.2 Visual Processing: Photoreceptors, Pathways, Color Vision, and Feature Detection 2.3 Auditory Systems, Pitch Perception, Gustation, and Olfaction 2.4 Somatosensation, Vestibular Senses, Perceptual Organization, and Theories of Perception
3 Chapter 3: Biological Drives, Consciousness, and Ethology
3.1 Sleep Architecture, Circadian Rhythms, and States of Consciousness 3.2 Biological Mechanisms of Hunger, Thirst, Sexual Behavior, and Emotion 3.3 Ethology and Comparative Psychology: Instincts, Imprinting, and Evolutionary Adaptation
4 Chapter 4: Principles of Conditioning and Learning
4.1 Classical Conditioning: Paradigms, Extinction, Spontaneous Recovery, and Biological Constraints 4.2 Operant Conditioning: Reinforcement Schedules, Punishment, and Behavior Modification 4.3 Observational Learning, Social Cognitive Theory, and Latent Learning
5 Chapter 5: Memory Architecture and Processes
5.1 Memory Architecture: Sensory Buffers, Working Memory, and Multi-Store Models 5.2 Long-Term Memory Systems: Episodic, Semantic, Procedural, and Implicit Memory 5.3 Retrieval Processes, Forgetting Curves, Interference Theory, and Memory Reconstruction
6 Chapter 6: Language, Thought, Decision Making, and Intelligence
6.1 Language Structure, Psycholinguistics, and Language Acquisition Theories 6.2 Concept Formation, Mental Representation, and Problem-Solving Strategies 6.3 Judgment, Heuristics, Cognitive Biases, and Decision-Making Models 6.4 Selective Attention, Divided Attention, and Executive Cognitive Control 6.5 Reading Processes, Bilingualism, and Verbal and Nonverbal Communication 6.6 Intelligence: Theories, Measurement, Heritability, and Metacognition
7 Chapter 7: Social Perception, Attribution, Attitudes, and the Self
7.1 Attribution Theories, Heider, Kelley, and Systematic Attribution Errors 7.2 Attitude Formation, Consistency Theories, and Cognitive Dissonance 7.3 Persuasion Models: Elaboration Likelihood Model and Persuasion Techniques 7.4 The Self, Social Comparison, Self-Esteem, and the Need to Belong
8 Chapter 8: Social Influence, Groups, Relationships, Culture, and Gender
8.1 Conformity, Compliance, and Obedience: Classic Studies and Mechanisms 8.2 Group Dynamics: Social Facilitation, Loafing, Polarization, and Groupthink 8.3 Stereotyping, Prejudice, Discrimination, and Intergroup Conflict 8.4 Prosocial Behavior, Bystander Intervention, Aggression, Interpersonal Attraction, and Close Relationships 8.5 Emotion, Affect, and Motivation in Social Life; Cultural and Gender Influences
9 Chapter 9: Physical, Cognitive, and Moral Development
9.1 Prenatal Development, Teratogens, Neonatal Reflexes, and Motor Milestones 9.2 Piaget's Cognitive Developmental Stages, Neo-Piagetian Theories, and Post-Piagetian Critiques 9.3 Vygotsky's Sociocultural Theory, Scaffolding, and the Zone of Proximal Development 9.4 Moral Development: Kohlberg's Stage Model and Gilligan's Care Perspective
10 Chapter 10: Social, Emotional, Gender, and Lifespan Development
10.1 Attachment Theory, Bowlby, Ainsworth's Strange Situation, and Temperament 10.2 Erikson's Psychosocial Stages and Baumrind's Parenting Typologies 10.3 Adolescent Identity Exploration, Adult Transitions, and Cognitive Changes in Aging 10.4 Emotional Development, Gender Development, Peer Relations, and Ecological Systems
11 Chapter 11: Theories of Personality
11.1 Psychodynamic and Neo-Freudian Personality Theories 11.2 Humanistic, Existential, and Phenomenological Approaches to Personality 11.3 Trait Theories: The Big Five (Five-Factor Model), Allport, Cattell, and Eysenck
12 Chapter 12: Psychological Disorders and Psychopathology
12.1 Anxiety Disorders, OCD, and Trauma- and Stressor-Related Disorders 12.2 Depressive Disorders, Bipolar and Related Disorders, and Suicide Risk 12.3 Schizophrenia Spectrum, Psychotic Disorders, and Personality Disorders 12.4 Neurodevelopmental, Eating, Substance-Related, Dissociative, Somatic Symptom, and Neurocognitive Disorders 12.5 Causes and Development of Disorders, Epidemiology, and Cultural and Gender Issues in Psychopathology
13 Chapter 13: Clinical Assessment, Treatment, Health Psychology, and Prevention
13.1 Clinical Assessment: Objective Inventories, Projective Tests, and Clinical Interviews 13.2 Psychotherapeutic Modalities: CBT, Behavioral, Psychodynamic, and Humanistic Therapies 13.3 Biological and Somatic Treatments: Psychotropic Medications and Neuromodulation 13.4 Stress, Conflict, Coping, Health Psychology, and Prevention
14 Chapter 14: Research Design and Experimental Methodology
14.1 The Scientific Method, Variables, and Operational Definitions 14.2 Between-Subjects, Within-Subjects, Quasi-Experimental, and Correlational Designs 14.3 Threats to Internal and External Validity, Demand Characteristics, and Experimenter Bias
15 Chapter 15: Statistical Analysis in Psychological Science
15.1 Descriptive Statistics, Measures of Central Tendency, Variability, and Normal Distributions 15.2 Inferential Statistics: Hypothesis Testing, Alpha Levels, Power, and Effect Sizes 15.3 Bivariate and Multivariate Techniques: t-Tests, ANOVA Models, Correlation, and Regression
16 Chapter 16: Psychometrics, Ethics, History, and Applied Psychology
16.1 Psychometric Theory: Classical Test Theory, Reliability Types, and Validity Constructs 16.2 Research Ethics, APA Ethical Principles, Institutional Review Boards, and Animal Welfare 16.3 Historical Foundations of Psychology, Major Schools of Thought, and Professional Milestones 16.4 Industrial-Organizational and Educational Psychology
1.3 Neurotransmitters, Neuromodulators, and Psychopharmacology
Key Takeaways Explain This Topic AI
Neurotransmitters are classified biochemically into small-molecule transmitters (acetylcholine, monoamines, amino acids) and neuropeptides (endorphins, substance P), operating through either fast ionotropic channels or slower metabotropic GPCR cascades.
Dopaminergic transmission is organized into four distinct functional pathways: mesolimbic (reward and incentive salience), mesocortical (executive function and cognition), nigrostriatal (motor initiation), and tuberoinfundibular (prolactin suppression).
Glutamate acts as the primary excitatory neurotransmitter mediating synaptic plasticity via AMPA and NMDA receptors (the latter acting as molecular coincidence detectors for Long-Term Potentiation), while GABA acts as the primary inhibitory neurotransmitter via GABAA chloride channels and GABAB potassium channels.
Psychotropic drugs exert therapeutic and adverse effects by altering neurochemical dynamics as receptor agonists, competitive/allosteric antagonists, reuptake inhibitors, or metabolic enzyme inhibitors across clinical categories.
Last updated: October 2026
Neurotransmitters, Neuromodulators, and Psychopharmacology
Intercellular communication in the nervous system relies on the release of specialized chemical messengers that diffuse across the synaptic cleft or act diffusely as neuromodulators. A chemical substance is classified as a classic neurotransmitter only if it satisfies four rigorous physiological criteria:
It is synthesized within the presynaptic neuron.
It is stored within presynaptic vesicles prior to release.
It is released in an activity-dependent manner triggered by presynaptic depolarization and calcium influx.
When applied experimentally to the postsynaptic cell, it mimics the exact physiological effect of natural presynaptic stimulation, and specific mechanisms exist to terminate its action. [ NEUROTRANSMITTERS ]
- │
- ┌─────────────────────────────────┼─────────────────────────────────┐
- ▼ ▼ ▼
- [ ACETYLCHOLINE ] [ MONOAMINES ] [ AMINO ACIDS ]
- ├── Nicotinic (Ionotropic) ├── Catecholamines: ├── Glutamate (Excitatory)
- └── Muscarinic (Metabotropic) │ ├── Dopamine (DA) │ ├── AMPA
- │ ├── Norepinephrine (NE) │ └── NMDA (Coincidence Detector)
- │ └── Epinephrine (Epi) └── GABA (Inhibitory)
- └── Indolamines: ├── GABAA (Cl- channel)
- └── Serotonin (5-HT) └── GABAB (K+ GPCR)
1. Acetylcholine (ACh)
Acetylcholine was the first neurotransmitter discovered, identified by Otto Loewi in 1921 ( Vagusstoff ) in his classic experiment demonstrating chemical neurotransmission between dual-perfused frog hearts.
Biosynthesis and Inactivation: Synthesized in the presynaptic cytoplasm from choline and acetyl coenzyme A (acetyl-CoA) via the enzyme choline acetyltransferase (ChAT) . Following exocytosis, ACh is rapidly inactivated within the synaptic cleft by acetylcholinesterase (AChE) into acetate and choline; high-affinity choline transporters then pump choline back into the terminal for re-synthesis.
Receptor Subtypes:
Nicotinic ACh Receptors (nAChR): Ionotropic, non-selective cation channels permeable to N a + Na^+ N a + and C a 2 + Ca^{2+} C a 2 + . Produce rapid, robust depolarizations (fast EPSPs). Found at the somatic neuromuscular junction (NMJ) , in autonomic ganglia, and in selected brain regions. Stimulated by nicotine; selectively blocked by curare (producing flaccid paralysis) and alpha-bungarotoxin.
Muscarinic ACh Receptors (mAChR): Metabotropic G-protein coupled receptors ( M 1 M_1 M 1 through M 5 M_5 M 5 ). Distributed widely throughout the central nervous system and on parasympathetic target organs. Blocked selectively by atropine (inducing mydriasis and tachycardia) and scopolamine (which impairs working memory and memory encoding).
Anatomical Pathways and Behavioral Roles:
Basal Forebrain: The nucleus basalis of Meynert and medial septal nuclei send widespread cholinergic projections throughout the neocortex and hippocampus, mediating sustained visual attention, wakefulness, and declarative memory encoding.
Brainstem: The pedunculopontine and laterodorsal tegmental nuclei project to the thalamus, modulating sleep-wake architecture and triggering REM sleep phenomena.
Clinical Correlates and Toxins:
Alzheimer's Disease: Characterized by early, selective neurodegeneration of cholinergic projection neurons within the nucleus basalis of Meynert, leading to severe cortical acetylcholine depletion. Standard symptomatic pharmacotherapies utilize acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) to prolong synaptic ACh availability.
Myasthenia Gravis: An autoimmune neuromuscular disorder in which circulating autoantibodies attack and destroy postsynaptic nicotinic ACh receptors at the neuromuscular junction, producing progressive skeletal muscle weakness and ptosis.
Botulinum Toxin ( Botox ): A bacterial protease that cleaves presynaptic SNARE proteins (SNAP-25), preventing acetylcholine exocytosis and causing flaccid paralysis.
Black Widow Spider Venom ( α \alpha α -Latrotoxin): Triggers massive, uncontrolled dumping of acetylcholine vesicles into the cleft, causing violent muscular spasms followed by receptor desensitization.
2. Monoamines: Catecholamines and Indolamines
Monoamines possess a single aromatic ring connected to an amino group by a two-carbon chain. They are subdivided into catecholamines (containing a catechol moiety) and indolamines .
The Catecholamine Biosynthetic Pathway
All catecholamines are synthesized through a shared, sequential biochemical pathway originating from the dietary essential amino acid L-tyrosine :
L-Tyrosine → (Rate-Limiting Step) + Tyrosine Hydroxylase (TH) L-DOPA → + AADC Dopamine → + DBH Norepinephrine → + PNMT Epinephrine \text{L-Tyrosine} \xrightarrow[\text{(Rate-Limiting Step)}]{+ \text{ Tyrosine Hydroxylase (TH)}} \text{L-DOPA} \xrightarrow{+ \text{ AADC}} \text{Dopamine} \xrightarrow{+ \text{ DBH}} \text{Norepinephrine} \xrightarrow{+ \text{ PNMT}} \text{Epinephrine} L-Tyrosine + Tyrosine Hydroxylase (TH) (Rate-Limiting Step) L-DOPA + AADC Dopamine + DBH Norepinephrine + PNMT Epinephrine
Tyrosine Hydroxylase (TH): Catalyzes the conversion of tyrosine to L-dihydroxyphenylalanine (L-DOPA). TH is the rate-limiting enzyme of the entire pathway; its activity is regulated by end-product feedback inhibition.
Aromatic L-Amino Acid Decarboxylase (AADC / DOPA Decarboxylase): Rapidly converts L-DOPA to Dopamine.
Dopamine β \beta β -Hydroxylase (DBH): Located inside synaptic vesicles of noradrenergic neurons; converts Dopamine to Norepinephrine.
Phenylethanolamine N-Methyltransferase (PNMT): Located in the adrenal medulla and medullary brainstem; converts Norepinephrine to Epinephrine.
Dopamine (DA): Pathways and Receptor Subtypes
Dopamine acts primarily as a neuromodulator via five metabotropic receptor subtypes categorized into two families:
D 1 D_1 D 1 -like Family ( D 1 , D 5 D_1, D_5 D 1 , D 5 ): Coupled to G s / G o l f G_s/G_{olf} G s / G o l f , stimulating adenylyl cyclase, elevating cyclic AMP (cAMP), and increasing protein kinase A (PKA) activity.
D 2 D_2 D 2 -like Family ( D 2 , D 3 , D 4 D_2, D_3, D_4 D 2 , D 3 , D 4 ): Coupled to G i / G o G_i/G_o G i / G o , inhibiting adenylyl cyclase, lowering cAMP, opening potassium channels, and acting as inhibitory presynaptic autoreceptors that suppress further dopamine release. [ DOPAMINERGIC PATHWAYS ]
- │
- ┌───────────────────────────┬──────┴────────────────────┬───────────────────────────┐
- ▼ ▼ ▼ ▼
- [ MESOLIMBIC ] [ MESOCORTICAL ] [ NIGROSTRIATAL ] [ TUBEROINFUNDIBULAR ]
- VTA ──> N. Accumbens VTA ──> Prefrontal Cortex S. Nigra ──> Striatum Hypothalamus ──> Pituitary
- Incentive salience - Executive function - Motor coordination - Tonically inhibits
- Positive symptoms - Negative/cognitive - Parkinson's deficits prolactin secretion
- of schizophrenia symptoms of schiz. - Antipsychotic EPS - Blockade causes
- Addiction / reward - Working memory - Tardive dyskinesia hyperprolactinemia
Mesolimbic Pathway: Originates in the ventral tegmental area (VTA) and projects to the nucleus accumbens , olfactory tubercle, and amygdala. Mediates incentive salience ("wanting" rather than "liking"), reinforcement learning, and motivation. All addictive drugs (cocaine, amphetamines, nicotine, opioids, alcohol) converge to elevate extracellular dopamine within this pathway. Hyperactivity of the mesolimbic pathway underlies the positive symptoms of schizophrenia (hallucinations, delusions).
Mesocortical Pathway: Originates in the VTA and projects to the prefrontal cortex. Governs working memory, cognitive flexibility, and emotional expression. Hypoactivity of mesocortical projections contributes to the negative symptoms (avolition, flat affect, anhedonia) and cognitive deficits of schizophrenia.
Nigrostriatal Pathway: Originates in the substantia nigra pars compacta ( S N c SNc SN c ) and projects to the dorsal striatum (caudate and putamen), containing roughly 80% of total brain dopamine. Degeneration of this tract produces Parkinson's disease . Conversely, therapeutic antagonism of D 2 D_2 D 2 receptors in this pathway by first-generation antipsychotics produces extrapyramidal symptoms (EPS) and, following chronic treatment, tardive dyskinesia .
Tuberoinfundibular Pathway: Originates in the arcuate nucleus of the hypothalamus and projects via the median eminence to the anterior pituitary gland, where dopamine acts as a neurohormone to tonically inhibit prolactin secretion . Antipsychotic drugs that block D 2 D_2 D 2 receptors disinhibit prolactin, leading to hyperprolactinemia (galactorrhea, gynecomastia, amenorrhea, and sexual dysfunction).
Norepinephrine and Epinephrine
Norepinephrine (NE / Noradrenaline):
Anatomy: Synthesized primarily within the locus coeruleus in the dorsal pons, which projects throughout the entire neocortex, thalamus, limbic system, cerebellum, and spinal cord.
Function: Regulates vigilance, sustained attention, fight-or-flight sympathetic arousal, and sleep-wake transitions. Firing rates are highest during novel or threatening stimuli and quiescent during REM sleep.
Adrenergic Receptors: Metabotropic receptors divided into α 1 \alpha_1 α 1 ( G q G_q G q ), α 2 \alpha_2 α 2 ( G i G_i G i autoreceptors that suppress NE exocytosis), and β 1 , β 2 , β 3 \beta_1, \beta_2, \beta_3 β 1 , β 2 , β 3 ( G s G_s G s ). Centrally acting β \beta β -blockers (e.g., propranolol ) attenuate peripheral autonomic arousal in performance anxiety and have been studied, with mixed results, as a way to weaken the reconsolidation of traumatic emotional memories.
Epinephrine (Adrenaline): Synthesized primarily in the adrenal medulla (chromaffin cells) under direct preganglionic sympathetic stimulation, operating predominantly as a systemic circulating hormone rather than a central neurotransmitter.
Indolamines: Serotonin (5-HT)
Serotonin (5-hydroxytryptamine, 5-HT) is synthesized from the essential dietary amino acid L-tryptophan :
L-Tryptophan → (Rate-Limiting Step) + Tryptophan Hydroxylase (TPH) 5-HTP → + AADC 5-HT \text{L-Tryptophan} \xrightarrow[\text{(Rate-Limiting Step)}]{+ \text{ Tryptophan Hydroxylase (TPH)}} \text{5-HTP} \xrightarrow{+ \text{ AADC}} \text{5-HT} L-Tryptophan + Tryptophan Hydroxylase (TPH) (Rate-Limiting Step) 5-HTP + AADC 5-HT
Anatomy: Central serotonergic neurons are concentrated almost exclusively within the brainstem Raphe nuclei (dorsal and median raphe in the midbrain and pons), which send diffuse projections throughout the forebrain, limbic system, and dorsal horns of the spinal cord.
Receptors: At least 14 distinct receptor subtypes grouped into seven families ( 5 -HT 1 5\text{-HT}_1 5 -HT 1 through 5 -HT 7 5\text{-HT}_7 5 -HT 7 ). All are metabotropic GPCRs except the 5 -HT 3 5\text{-HT}_3 5 -HT 3 receptor, which is an ionotropic ligand-gated cation channel (antagonized by the antiemetic ondansetron). The 5 -HT 2 A 5\text{-HT}_{2A} 5 -HT 2 A receptor ( G q G_q G q ) is the primary site of action for classic hallucinogens (LSD, psilocybin, mescaline).
Functions and Inactivation: Modulates mood, affect, anxiety, sleep-wake cycles, appetite (satiety), thermal regulation, and pain transmission. Inactivated by the serotonin transporter (SERT) and degraded intracellularly by monoamine oxidase A (MAO-A) .
3. Amino Acid Neurotransmitters: Glutamate and GABA
Amino acids are the workhorses of fast synaptic transmission, responsible for >90% of synaptic traffic in the CNS.
Glutamate
Glutamate is the universal excitatory neurotransmitter in the mammalian central nervous system, synthesized from glutamine by the mitochondrial enzyme glutaminase . [ GLUTAMATE RECEPTORS ]
- │
- ┌────────────────────────────┴────────────────────────────┐
- ▼ ▼
- [ IONOTROPIC RECEPTORS ] [ METABOTROPIC (mGluRs) ]
- ├── AMPA Receptor: Fast Na+ influx ├── Group I (mGluR1,5): Gq coupled
- ├── Kainate Receptor: Modulatory cation channel └── Group II/III: Gi coupled (autoreceptors)
- └── NMDA Receptor: Molecular Coincidence Detector
- Highly permeable to Ca2+ and Na+
- Blocked at rest by extracellular Mg2+ ion
- Requires Depolarization + Glutamate + Glycine
- Cellular substrate of Long-Term Potentiation (LTP)
The NMDA Receptor as a Coincidence Detector:
At resting membrane potentials (-70 mV), the NMDA receptor pore is physically obstructed by an extracellular magnesium ion ( M g 2 + Mg^{2+} M g 2 + ) held in place by intracellular negative charge.
Opening the channel requires two simultaneous conditions: (1) Glutamate binding (along with co-agonist glycine or D-serine), and (2) Membrane depolarization (typically provided by adjacent AMPA receptor activation), which electrostatically expels the M g 2 + Mg^{2+} M g 2 + plug from the pore.
Once unblocked, NMDA channels permit robust C a 2 + Ca^{2+} C a 2 + influx along with N a + Na^+ N a + . This intracellular C a 2 + Ca^{2+} C a 2 + surge acts as a second messenger, activating calcium/calmodulin-dependent protein kinase II ( CaMKII ), which inserts additional AMPA receptors into the postsynaptic density, establishing Long-Term Potentiation (LTP) —the cellular foundation of learning and memory.
Excitotoxicity: Impaired astrocytic glutamate uptake or prolonged ischemic insults (e.g., stroke) result in massive, pathological accumulation of glutamate in the cleft. Uncontrolled NMDA activation drives excessive, lethal C a 2 + Ca^{2+} C a 2 + influx, activating intracellular proteases (calpains), endonucleases, and phospholipases that dismantle the neuron, resulting in apoptotic and necrotic cell death.
GABA ( γ \gamma γ -Aminobutyric Acid)
GABA is the primary inhibitory neurotransmitter in the mature mammalian brain, synthesized directly from glutamate by the enzyme glutamic acid decarboxylase (GAD) , which requires the cofactor pyridoxal phosphate (Vitamin B 6 B_6 B 6 ) .
GABA A \text{GABA}_A GABA A Receptor: A heteropentameric ionotropic ligand-gated chloride ( C l − Cl^- C l − ) channel . Channel opening allows C l − Cl^- C l − to flow inward down its chemical gradient, hyperpolarizing the membrane or holding it below threshold (shunting inhibition). The GABA A \text{GABA}_A GABA A macromolecular complex contains distinct allosteric modulatory binding sites:
Benzodiazepines (e.g., diazepam, lorazepam): Bind to a distinct allosteric pocket between α \alpha α and γ \gamma γ subunits, increasing the frequency of channel opening in the presence of GABA.
Barbiturates (e.g., phenobarbital, thiopental): Bind to an alternate site, increasing the duration of channel opening ; at high concentrations, barbiturates can open the pore directly in the absence of GABA, accounting for their narrow therapeutic window and fatal overdose potential via respiratory depression.
Ethanol: Allosterically enhances GABA A \text{GABA}_A GABA A chloride conductance while simultaneously inhibiting NMDA glutamate receptors.
GABA B \text{GABA}_B GABA B Receptor: A heterodimeric metabotropic GPCR coupled to G i / G o G_i/G_o G i / G o . Stimulates opening of inward-rectifying potassium channels ( K + K^+ K + efflux) and inhibits presynaptic voltage-gated calcium channels, generating slow, prolonged inhibitory postsynaptic potentials. Selectively stimulated by the muscle relaxant baclofen .
Note
In the spinal cord and lower brainstem, Glycine serves as the primary inhibitory neurotransmitter, opening ionotropic chloride channels. It is selectively antagonized by the poison strychnine , which induces lethal, uncontrolled muscular convulsions by uninhibiting spinal motor neurons.
4. Neuropeptides and Psychopharmacology
Neuropeptides are large polymers composed of 3 to 40 amino acids, synthesized in the soma, packaged into dense-core vesicles, and transported down the axon via fast axonal transport. They act at low concentrations with high affinity at metabotropic receptors, often co-released with small-molecule neurotransmitters:
Endorphins and Enkephalins: Endogenous opioid peptides derived from precursor proteins (e.g., pro-opiomelanocortin / POMC). Bind to μ \mu μ , δ \delta δ , and κ \kappa κ opioid GPCRs in the periaqueductal gray and dorsal horn to suppress pain transmission and activate dopamine release in the mesolimbic reward system by inhibiting GABAergic interneurons. Blocked by competitive opioid antagonists like naloxone (Narcan) .
Substance P: An 11-amino acid tachykinin peptide released by primary nociceptive C-fibers in the spinal dorsal horn, transmitting slow, burning pain sensations. Depleted by repeated exposure to capsaicin .
Psychopharmacological Classes and Synaptic Mechanisms
Drug Class Representative Agents Primary Synaptic Mechanism Clinical Applications & High-Yield Side Effects
SSRIs Fluoxetine, Sertraline, Escitalopram Selectively blocks the serotonin transporter ( SERT ), prolonging 5-HT signaling. First-line for Major Depression, OCD, Panic Disorder; delay in efficacy (2–4 weeks) relates to 5 -HT 1 A 5\text{-HT}_{1A} 5 -HT 1 A autoreceptor desensitization.
SNRIs Venlafaxine, Duloxetine Inhibits reuptake of both serotonin (SERT) and norepinephrine (NET). Depression, generalized anxiety, neuropathic pain; can elevate blood pressure.
Tricyclic Antidepressants (TCAs) Amitriptyline, Imipramine Blocks SERT and NET; also blocks muscarinic, α 1 \alpha_1 α 1 -adrenergic, and H 1 H_1 H 1 histamine receptors. Highly lethal in overdose due to cardiac sodium channel blockade (fatal arrhythmias); strong anticholinergic side effects (dry mouth, urinary retention).
MAO Inhibitors (MAOIs) Phenelzine, Tranylcypromine Irreversibly inhibits monoamine oxidase (MAO-A & MAO-B), preventing degradation of DA, NE, and 5-HT. Atypical depression; requires strict dietary avoidance of tyramine -rich foods (aged cheeses, wine, cured meats) to prevent lethal hypertensive crises ("cheese reaction").
First-Generation Antipsychotics (Typical) Haloperidol, Chlorpromazine High-affinity competitive antagonists at postsynaptic D 2 D_2 D 2 receptors (especially in mesolimbic and nigrostriatal tracts). Treats positive psychotic symptoms; high risk of extrapyramidal symptoms (EPS) , dystonia, parkinsonism, and irreversible tardive dyskinesia .
Second-Generation Antipsychotics (Atypical) Clozapine, Risperidone, Olanzapine Antagonism at both D 2 D_2 D 2 and 5 -HT 2 A 5\text{-HT}_{2A} 5 -HT 2 A receptors ; lower affinity at D 2 D_2 D 2 . Treats positive and negative symptoms with lower EPS risk; side effects include metabolic syndrome, weight gain, and agranulocytosis (clozapine requires regular absolute neutrophil monitoring).
Psychostimulants D-Amphetamine, Methylphenidate Amphetamine reverses DAT/NET transporters and inhibits VMAT2; Methylphenidate blocks DAT/NET reuptake. First-line for ADHD, narcolepsy; elevates catecholamines in the prefrontal cortex and nucleus accumbens.